Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
In order to study alternatives at the tissue biopsy to study EGFR status in NSCLC patients, we evaluated three different liquid biopsy platforms (plasma, urine and exhaled breath condensate, EBC). We also reviewed the literature of the cfDNA biological sources other than plasma and compared our resu...
Guardado en:
Autores principales: | Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/baf6dfbf7bf446ec935f7672e54ef210 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Kazutaka Fujita, et al.
Publicado: (2021) -
Fragmentomic cfDNA Patterns in Noninvasive Prenatal Testing and Beyond
por: Kavish Kohabir, et al.
Publicado: (2021) -
Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
por: Elmo W. I. Neuberger, et al.
Publicado: (2021) -
Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
por: Xiaorong Zhou, et al.
Publicado: (2021) -
Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
por: Keita Tanaka, et al.
Publicado: (2021)